N-methyl-1-quinoxalin-6-ylmethanamine | 179873-39-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-methyl-1-quinoxalin-6-ylmethanamine
• CAS: 179873-39-3
• 化学式: C₁₀H₁₁N₃
• 分子量: 173.217
• InChiKey: QRZKMXOFPHWLCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(trifluoroacetyl)thiophene-2-carboxylic acid 、 N-methyl-1-quinoxalin-6-ylmethanamine 在 PS-DCC 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 N-methyl-N-(quinoxalin-6-ylmethyl)-5-(trifluoroacetyl)thiophene-2-carboxamide
  参考文献：
  名称：

  Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors

  摘要：

  5-(Trifluoroacetyl)thiophene-2-carboxamides were found to be potent and selective class II HDAC inhibitors. This paper describes their further development and the investigation on the cause for the lack of cell-based activity. A rapid screening assay was set up which enabled the identification of more metabolic stable compounds as potent and selective class II HDAC inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.041

文献信息

• [EN] RESORCINOL N-ARYL AMIDE COMPOUNDS, FOR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS<br/>[FR] COMPOSÉS DE RÉSORCINOL N-ARYLAMIDE DESTINÉS À ÊTRE UTILISÉS COMME INHIBITEURS DE PYRUVATE DÉSHYDROGÉNASE KINASE
  申请人：VERNALIS R & D LTD

  公开号：WO2015040425A1

  公开（公告）日：2015-03-26

  A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: Y is –CONR1- or optionally substituted arylene or optionally substituted heteroarylene; R1 is H, Cl, F, CH3 or CF3; 10 each R4 is independently H, CH3 or F; R5 is H or CH3; and each R2 and R6 is independently (Alk)n-Rn-(Alk)n-Rn-(Alk)n-X; The compounds of the invention are useful as resorcinol N-aryl amide (NAA) compounds, which are suitable for use as PDK inhibitors, for example for 15 inhibition of cancer cell proliferation.

  一种具有以下结构的化合物：或其药用可接受的盐，其中：Y为–CONR1-或可选择地取代的芳基或可选择地取代的杂芳基；R1为H、Cl、F、CH3或CF3；每个R4独立地为H、 或F；R5为H或 ；每个R2和R6独立地为(Alk)n-Rn-(Alk)n-Rn-(Alk)n-X；该发明的化合物可用作间苯二酚N-芳基酰胺（NAA）化合物，适用于用作PDK抑制剂，例如用于抑制癌细胞增殖。
• 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors
  作者：Philip Jones、Matthew J. Bottomley、Andrea Carfí、Ottavia Cecchetti、Federica Ferrigno、Paola Lo Surdo、Jesus M. Ontoria、Michael Rowley、Rita Scarpelli、Carsten Schultz-Fademrecht、Christian Steinkühler

  DOI：10.1016/j.bmcl.2008.02.026

  日期：2008.6

  HDAC inhibitors has been hampered by lack of efficient enzyme assays, in the preceding paper two assays have been developed to improve the efficiency of these enzymes: mutating an active site histidine to tyrosine, or by the use of a trifluoroacetamide lysine substrate, allowing screening to identify class II HDAC inhibitors. Herein, 2-trifluoroacetylthiophenes have been demonstrated to inhibit class

  II类HDAC抑制剂的鉴定因缺乏有效的酶检测而受阻，在前一篇论文中，开发了两种检测以提高这些酶的效率：将活性位点组氨酸突变为酪氨酸，或使用三氟乙酰胺赖氨酸底物，可进行筛选以鉴定II类HDAC抑制剂。在本文中，已经证明2-三氟乙酰基噻吩抑制II类HDAC，从而导致开发出一系列5-（三氟乙酰基）噻吩-2-甲酰胺，它们是新颖的，有效的和选择性的II类HDAC抑制剂。具有结合的抑制剂的HDAC 4催化域的X射线晶体结构表明，这些化合物是活性位点抑制剂，并以其水合形式结合。
• Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs)
  作者：Swati P. Mercer、Anthony J. Roecker、Susan Garson、Duane R. Reiss、C. Meacham Harrell、Kathy L. Murphy、Joseph G. Bruno、Rodney A. Bednar、Wei Lemaire、Donghui Cui、Tamara D. Cabalu、Cuyue Tang、Thomayant Prueksaritanont、George D. Hartman、Steven D. Young、Christopher J. Winrow、John J. Renger、Paul J. Coleman

  DOI：10.1016/j.bmcl.2013.10.045

  日期：2013.12

  receptor antagonists (2-SORAs) has been hampered by the lack of orally bioavailable, highly selective small molecule probes. Herein, the discovery and optimization of a novel series of 2,5-diarylnicotinamides as potent and orally bioavailable orexin-2 receptor selective antagonists is described. A compound from this series demonstrated potent sleep promotion when dosed orally to EEG telemetrized rats

  由于过去十年中发现的大量生物学和遗传数据，食欲素（或降血糖素）系统已被确定为治疗失眠的新靶标。最近，使用双重（OX 1 R / OX 2R）食欲素受体拮抗剂。但是，由于缺乏口服生物利用度高选择性小分子探针，阻碍了与选择性orexin-2受体拮抗剂（2-SORA）相关的药理学研究。在此，描述了发现和优化作为有效的和口服生物利用的orexin-2受体选择性拮抗剂的2，5-二芳基烟酰胺的新系列。当从脑电图遥测大鼠口服给药时，该系列化合物显示出有效的睡眠促进作用。
• AZETIDINE SULFONAMIDE COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP4082611A1

  公开（公告）日：2022-11-02

  An object of the present invention is to provide a compound useful as a therapeutic drug for an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis of SLE patients by suppressing immune cell function by inhibiting proliferation of activated T cells and production of interferon alpha (IFN-α). The present invention provides a compound represented by formula (I): wherein R1, R2 and R3 are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.

  本发明的目的是提供一种化合物，通过抑制激活T细胞的增殖和干扰素α（IFN-α）的产生来抑制免疫细胞功能，作为治疗自身免疫性疾病，如全身性红斑狼疮（SLE）和SLE患者的肾炎的治疗药物。本发明提供一种由式（I）表示的化合物：其中R1、R2和R3与说明书中定义的相同，或其药学上可接受的盐。
• [EN] SUBSTITUTED PYRIMIDINE-4-FORMIC ACID DERIVATIVE, HERBICIDAL COMPOSITION AND USE THEREOF<br/>[FR] DÉRIVÉ D'ACIDE PYRIMIDINE-4-FORMIQUE SUBSTITUÉ, COMPOSITION HERBICIDE ET SON UTILISATION<br/>[ZH] 一种取代的嘧啶-4-甲酸衍生物及其除草组合物和用途
  申请人：QINGDAO KINGAGROOT CHEMICAL COMPOUND CO LTD

  公开号：WO2019227771A1

  公开（公告）日：2019-12-05

  一种取代的嘧啶-4-甲酸衍生物及其除草组合物，该嘧啶-4-甲酸衍生物及其除草组合物具有优异的除草活性和作物选择性。